Current aspects in hemoglobin A1c detection: A review

Clinica Chimica Acta

Volumn 439, Issue , 2015, Pages 202-211

  Ang, Shu Hwang ^a   Thevarajah, M ^a   Alias, Yatimah ^a   Khor, Sook Mei ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Biosensors; Hemoglobin A1c tests; IFCC (International Federation of Clinical Chemistry and Laboratory Medicine); NGSP (National Glycohemoglobin Standardization Program); POC technology; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBIN A1C PROTEIN, HUMAN;

AMPEROMETRIC BIOSENSOR; BIOCHIP; BIOSENSOR; BLOOD ANALYSIS; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC VALUE; FASTING PLASMA GLUCOSE; GLUCOSE BLOOD LEVEL; HEALTH CARE MANAGEMENT; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; IMMUNOSENSOR; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POINT OF CARE TESTING; RANDOM PLASMA GLUCOSE; REVIEW; STANDARDIZATION; BLOOD; DIABETES MELLITUS, TYPE 2; HUMANS; STANDARDS;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 84909952745     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.019     Document Type: Review

References (77)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
2. Greenberg R.A., Sacks D.B. Screening for diabetes: is it warranted?. Clin Chim Acta 2002, 315:61-69.
3. Alberti K.G.M.M., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
4. Hare M.J.L., Shaw J.E., Zimmet P.Z. Current controversies in the use of haemoglobin A1c. J Intern Med 2012, 271:227-236.
5. Lenters-Westra E., Schindhelm R.K., Bilo H.J., Slingerland R.J. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract 2013, 99:75-84.
6. Chen B., Bestetti G., Day R.M., Turner A.P.F. The synthesis and screening of a combinatorial peptide library for affinity ligands for glycosylated haemoglobin. Biosens Bioelectron 1998, 13:779-785.
7. Zhang Q., Tang N., Schepmoes A.A., Phillips L.S., Smith R.D., Metz T.O. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Proteome Res 2008, 7:2025-2032.
8. Goodall I. HbA1c standardisation destination-global IFCC Standardisation. How, why, where and when-a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes. Clin Biochem Rev/Aust Assoc Clin Biochem 2005, 26:5-19.
9. Lapolla A., Molin L., Traldi P. Protein glycation in diabetes as determined by mass spectrometry. Int J Endocrinol 2013, 2013:11.
10. Bain B.J. Haemoglobinopathy diagnosis: algorithms, lessons and pitfalls. Blood Rev 2011, 25:205-213.
11. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIoHN. For people of African, Mediterranean, or Southeast Asian heritage: important information about diabetes blood tests.
12. Little R.R., Roberts W.L. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 2009, 3:446-451.
13. Association A.D. Standards of medical care in diabetes-2011. Diabetes Care 2011, 34:S11-S61.
14. Standards of medical care in diabetes-2010 Diabetes care 2010, 33. (Suppl. 1:S11-61).
15. Sacks D.B. A1C versus glucose testing: a comparison. Diabetes Care 2011, 34:518-523.
16. Sacks D.B., Arnold M., Bakris G.L., et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34:e61-e99.
17. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of A WHO/IDF consultation 2006.
18. Johnson S.L., Tabaei B.P., Herman W.H. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74years of age. Diabetes Care 2005, 28:307-311.
19. Herman W.H. Diabetes epidemiology: guiding clinical and public health practice: the Kelly West Award Lecture, 2006. Diabetes Care 2007, 30:1912-1919.
20. Sacks D.B., Bruns D.E., Goldstein D.E., Maclaren N.K., McDonald J.M., Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002, 48:436-472.
21. Bennett C.M., Guo M., Dharmage S.C. HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007, 24:333-343.
22. Ma H., Gao X., Lin H.D., et al. Glycated haemoglobin in diagnosis of diabetes mellitus and pre-diabetes among middle-aged and elderly population: Shanghai Changfeng Study. Biomed Environ Sci 2013, 26:155-162.
23. Association A.D. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33:S62-S69.
24. WHO Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation 2011.
25. Dagogo-Jack S. Pitfalls in the use of HbA(1c) as a diagnostic test REPLY. Nat Rev Endocrinol 2011, 7.
26. Law L.S.C., Tso A.W.K., Tam S., Wat N.M.S., Cheung B.M.Y., Lam K.S.L. Haemoglobin A1c is superior to fasting glucose in predicting the incidence of diabetes over 8years among Chinese. Diabetes Res Clin Pract 2011, 91:e53-e56.
27. Heianza Y., Arase Y., Fujihara K., et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabetic medicine. J Br Diabet Assoc 2012, 29:e279-e285.
28. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
29. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412. (Clinical research ed).
30. Little R.R., Rohlfing C.L. HbA1c standardization: background, progress and current issues. Lab Med 2009, 40:368-373.
31. NGSP Protocol 2010.
32. Randie.R.Little PaCLR. HbA1c. An overview of current analytical testing issues. Clin Lab News 2011, 37.
33. NGSP International federation of clinical chemistry (IFCC) standardization of HbA1c 2010.
34. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008, 31:1473-1478.
35. Hanas R., John W.G. The international Hb AcCC. 2013 update on the worldwide standardization of the HbA1c measurement. Diabet Med 2013, 30:885-886.
36. Landin-Olsson Mona, J-OJ, Gunnar Nordin HbA1c - new standards introduced in Sweden; the new unit is mmol/mol. Läkartidningen 2010, 107:3282-3285.
37. Kashiwagi A. Development of the HbA1c international standardization of HbA1c measurement in Japan Diabetes Society, Rinsho byori The Japanese. J Clin Pathol 2013, 61:585-593.
38. Jeppsson J.O., Kobold U., Barr J., et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med CCLM/FESCC 2002, 40:78-89.
39. Rohlfing C.L., Wiedmeyer H.-M., Little R.R., England J.D., Tennill A., Goldstein D.E. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the diabetes control and complications trial. Diabetes Care 2002, 25:275-278.
40. Finke A., Kobold U., Hoelzel W., Weykamp C., Miedema K., Jeppsson J.O. Preparation of a candidate primary reference material for the international standardisation of HbA1c determinations. Clin chem Lab Med: CCLM/FESCC 1998, 36:299-308.
41. Lahousen T., Roller R.E., Lipp R.W., Schnedl W.J. Silent haemoglobin variants and determination of HbA(1c) with the HPLC bio-rad variant II. J Clin Pathol 2002, 55:699-703.
42. John W.G., Braconnier F., Miedema K., Aulesa C., Piras G. Evaluation of the Menarini-Arkray HA 8140 hemoglobin A1c analyzer. Clin Chem 1997, 43:968-975.
43. Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia 2004, 47:1143-1148.
44. Thevarajah M., Nadzimah M.N., Chew Y.Y. Interference of hemoglobinA1c (HbA1c) detection using ion-exchange high performance liquid chromatography (HPLC) method by clinically silent hemoglobin variant in University Malaya Medical Centre (UMMC)-a case report. Clin Biochem 2009, 42:430-434.
45. Rohlfing C.L., Connolly S.M., England J.D., et al. The effect of elevated fetal hemoglobin on hemoglobin A1c results: five common hemoglobin A1c methods compared with the IFCC reference method. Am J Clin Pathol 2008, 129:811-814.
46. HbA1c methods. Effects of hemoglobin variants (HbC, HbS, HbE and HbD traits) and elevated fetal hemoglobin (HbF) 2013.
47. Barman I., Dingari N.C., Kang J.W., Horowitz G.L., Dasari R.R., Feld M.S. Raman spectroscopy-based sensitive and specific detection of glycated hemoglobin. Anal Chem 2012, 84:2474-2482.
48. Chen S.-P., Yu X.-D., Xu J.-J., Chen H.-Y. Gold nanoparticles-coated magnetic microspheres as affinity matrix for detection of hemoglobin A1c in blood by microfluidic immunoassay. Biosens Bioelectron 2011, 26:4779-4784.
49. Lenters-Westra E., Slingerland R.J. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010, 56:44-52.
50. Holmes E.W., Erşahin Ç., Augustine G.J., et al. Analytic bias among certified methods for the measurement of hemoglobin A1c: a cause for concern?. Am J Clin Pathol 2008, 129:540-547.
51. Schwartz K.L., Monsur J., Hammad A., Bartoces M.G., Neale A.V. Comparison of point of care and laboratory HbA1c analysis: a MetroNet Study. J Am Board Family Med 2009, 22:461-463.
52. Lenters-Westra E., Slingerland R.J. Hemoglobin A1c point-of-care assays; a new world with a lot of consequences!. J Diabetes Sci Technol 2009, 3:418-423.
53. Bode B.W., Irvin B.R., Pierce J.A., Allen M., Clark A.L. Advances in hemoglobin A1c point of care technology. J Diabetes Sci Technol 2007, 1:405-411.
54. Sanchez-Mora C., M SR-O, Fernandez-Riejos P., et al. Evaluation of two HbA1c point-of-care analyzers. Clin Chem Lab Med: CCLM/FESCC 2011, 49:653-657.
55. Carter A.W. An analysis of the assessment of glycated hemoglobin using A1cNow+point-of-care device compared to central laboratory testing-an important addition to pharmacist-managed diabetes programs?. J diabetes Sci Technol 2008, 2:828-830.
56. Pundir C.S., Chawla S. Determination of glycated hemoglobin with special emphasis on biosensing methods. Anal Biochem 2014, 444:47-56.
57. Halámek J., Wollenberger U., Stöcklein W.F.M., Warsinke A., Scheller F.W. Signal amplification in immunoassays using labeling via boronic acid binding to the sugar moiety of immunoglobulin G: proof of concept for glycated hemoglobin. Anal Lett 2007, 40:1434-1444.
58. Xue Q., Bian C., Tong J., Sun J., Zhang H., Xia S. A micro potentiometric immunosensor for hemoglobin-A1c level detection based on mixed SAMs wrapped nano-spheres array. Biosens Bioelectron 2011, 26:2689-2693.
59. Chen H.-H., Wu C.-H., Tsai M.-L., Huang Y.-J., Chen S.-H. Detection of total and A1c-glycosylated hemoglobin in human whole blood using sandwich immunoassays on polydimethylsiloxane-based antibody microarrays. Anal Chem 2012, 84:8635-8641.
60. Liu J.-T., Chen L.-Y., Shih M.-C., Chang Y., Chen W.-Y. The investigation of recognition interaction between phenylboronate monolayer and glycated hemoglobin using surface plasmon resonance. Anal Biochem 2008, 375:90-96.
61. Song S.Y., Yoon H.C. Boronic acid-modified thin film interface for specific binding of glycated hemoglobin (HbA1c) and electrochemical biosensing. Sensors Actuators B Chem 2009, 140:233-239.
62. Hsieh K.-M., Lan K.-C., Hu W.-L., Chen M.-K., Jang L.-S., Wang M.-H. Glycated hemoglobin (HbA1c) affinity biosensors with ring-shaped interdigital electrodes on impedance measurement. Biosens Bioelectron 2013, 49:450-456.
63. Fang L., Li W., Zhou Y., Liu C.-C. A single-use, disposable iridium-modified electrochemical biosensor for fructosyl valine for the glycoslated hemoglobin detection. Sensors Actuators B Chem 2009, 137:235-238.
64. Chawla S., Pundir C.S. An amperometric hemoglobin A1c biosensor based on immobilization of fructosyl amino acid oxidase onto zinc oxide nanoparticles-polypyrrole film. Anal Biochem 2012, 430:156-162.
65. Echouffo-Tcheugui J.B., Ali M.K., Griffin S.J., Narayan K.M.V. Screening for type 2 diabetes and dysglycemia. Epidemiol Rev 2011, 33:63-87.
66. Karve A., Hayward R.A. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 2010, 33:2355-2359.
67. Goldenberg R., Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2013, 37:S8-S11. Supplement 1.
68. Suzuki Hiroshi, EO, YA Comparison between prediabetes defined by hemoglobin A1c (A1C) 5.7-6.4% and that defined by impaired fasting glucose (IFG) in a Japanese population. J Diabet Metab 2011, 2:2-4.
69. Lorenzo C., Wagenknecht L.E., Hanley A.J., Rewers M.J., Karter A.J., Haffner S.M. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010, 33:2104-2109.
70. Zhou X., Pang Z., Gao W., et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care 2010, 33:545-550.
71. Tankova T., Chakarova N., Dakovska L., Atanassova I. Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes. Acta Diabetol 2012, 49:371-378.
72. Mannarino M., Tonelli M., Allan G.M. Tools for practice: screening and diagnosis of type 2 diabetes with HbA1c. Can Fam Physician Med Fam Can 2013, 59:42.
73. Fajans S.S., Herman W.H., Oral E.A. Insufficient sensitivity of hemoglobin A1C determination in diagnosis or screening of early diabetic states. Metabolism 2011, 60:86-91.
74. Prevention or delay of type 2 diabetes. Diabetes care 2004, 27:s47.
75. Cole A., Nathan D.M., Savaria-Porter E., et al. An algorithm for the care of type 2 diabetes. Crit Pathways Cardiol 2009, 8:156-165.
76. Mayo Medical Laboratories, Hemoglobin A1c and Estimated Average Glucose, Diabetes Treatment Goals.Accessible on October 23rd, 2014 http://www.mayomedicallaboratories.com/articles/hottopics/transcripts/2009/2009-7a-hba1c/7a-12.html.
77. Gomez-Perez F.J., Aguilar-Salinas C.A., Almeda-Valdes P., Cuevas-Ramos D., Lerman Garber I., Rull J.A. HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res 2010, 41:302-308.